Log in

Relevant bibliographies by topics / Activité antivasculaire / Journal articles

To see the other types of publications on this topic, follow the link: Activité antivasculaire.

Journal articles on the topic 'Activité antivasculaire'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Activité antivasculaire.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Brenner, A. J., Y. Cohen, E. Breitbart, J. Rogge, and F. J. Giles. "Antivascular activity of VB111 in glioblastoma xenografts." Journal of Clinical Oncology 28, no. 15_suppl (2010): e13652-e13652. http://dx.doi.org/10.1200/jco.2010.28.15_suppl.e13652.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Garkavtsev, I., V. P. Chauhan, H. K. Wong, et al. "Dehydro- -lapachone, a plant product with antivascular activity." Proceedings of the National Academy of Sciences 108, no. 28 (2011): 11596–601. http://dx.doi.org/10.1073/pnas.1104225108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Korodi, Andrei Dan, Cristian Furau, Gheorghe Furau, et al. "Tipurile de vase asociate tumorilor GIST influenteaza eficienta terapiei antivasculare cu inhibitori de receptor tirozin-kinazic." Revista de Chimie 70, no. 9 (2019): 3250–53. http://dx.doi.org/10.37358/rc.19.9.7528.

Full text

Abstract:

Gastrointestinal stromal tumors (GIST�sare the most common mesenchymal neoplasms of the alimentary tract. Angiogenesis is an essential condition in the growth and development of tumors, especially in the case of GISTs due to their particular behavior. The aggressive behavior depends on the size and site of the tumor in close relationship with the intratumoral vascular development. The purpose of this study is to investigate, using immunohistochemical stainings, the types of intratumoral vessels in GIST�s, knowing the interrelation between the tumor angiogenesis and the response to the targeted

APA, Harvard, Vancouver, ISO, and other styles

4

Liang, Pingping, Xiaoyu Huang, Ya Wang, et al. "Tumor-Microenvironment-Responsive Nanoconjugate for Synergistic Antivascular Activity and Phototherapy." ACS Nano 12, no. 11 (2018): 11446–57. http://dx.doi.org/10.1021/acsnano.8b06478.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lee, Hsueh-Yun, Chih-Yi Chang, Mei-Jung Lai, et al. "Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes." Bioorganic & Medicinal Chemistry 23, no. 15 (2015): 4230–36. http://dx.doi.org/10.1016/j.bmc.2015.06.043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Aribi, Fallia, Charlene Vey, Derya Topkaya, et al. "Phthalocyanine-chalcone conjugates." Journal of Porphyrins and Phthalocyanines 20, no. 01n04 (2016): 497–504. http://dx.doi.org/10.1142/s1088424616500310.

Full text

Abstract:

A phthalocyanine-chalcone conjugate was previously reported to retain the full photodynamic activity of the phthalocyanine and a slightly lowered antivascular effect of the chalcone. Assuming that it was due to an insufficient release of the chalcone, we described here several grafting modes applied to the preparation of phthalocyanine-chalcone conjugates.

APA, Harvard, Vancouver, ISO, and other styles

7

Beale, Thomas M., Rebecca M. Myers, James W. Shearman, et al. "Antivascular and anticancer activity of dihalogenated A-ring analogues of combretastatin A-4." MedChemComm 1, no. 3 (2010): 202. http://dx.doi.org/10.1039/c0md00095g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ferl, G. Z., and R. E. Port. "Quantification of Antiangiogenic and Antivascular Drug Activity by Kinetic Analysis of DCE-MRI Data." Clinical Pharmacology & Therapeutics 92, no. 1 (2012): 118–24. http://dx.doi.org/10.1038/clpt.2012.63.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Tuncel, Sinem, Aurélien Trivella, Devrim Atilla, et al. "Assessing the Dual Activity of a Chalcone–Phthalocyanine Conjugate: Design, Synthesis, and Antivascular and Photodynamic Properties." Molecular Pharmaceutics 10, no. 10 (2013): 3706–16. http://dx.doi.org/10.1021/mp400207v.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Salimi, F., J. Hamedi, E. Motevaseli, and F. Mohammadipanah. "Isolation and screening of rareActinobacteria, a new insight for finding natural products with antivascular calcification activity." Journal of Applied Microbiology 124, no. 1 (2017): 254–66. http://dx.doi.org/10.1111/jam.13605.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Wang, Fang, Zhuang Yang, Yibin Liu, et al. "Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity." Bioorganic & Medicinal Chemistry 23, no. 13 (2015): 3337–50. http://dx.doi.org/10.1016/j.bmc.2015.04.055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Romagnoli, Romeo, Pier Giovanni Baraldi, Maria Kimatrai Salvador, et al. "Synthesis, Antimitotic and Antivascular Activity of 1-(3′,4′,5′-Trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles." Journal of Medicinal Chemistry 57, no. 15 (2014): 6795–808. http://dx.doi.org/10.1021/jm5008193.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Ducki, Sylvie, David Rennison, Meiko Woo, et al. "Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity." Bioorganic & Medicinal Chemistry 17, no. 22 (2009): 7698–710. http://dx.doi.org/10.1016/j.bmc.2009.09.039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Aikins, Anastasia R., MiJung Kim, Bernardo Raymundo, and Chan-Wha Kim. "Featured Article: Downregulation of transgelin blocks interleukin-8 utilization and suppresses vasculogenic mimicry in breast cancer cells." Experimental Biology and Medicine 242, no. 6 (2017): 573–83. http://dx.doi.org/10.1177/1535370216685435.

Full text

Abstract:

Vasculogenic mimicry (VM) is a non-classical mechanism recently described in many tumors, whereby cancer cells, rather than endothelial cells, form blood vessels. Transgelin is an actin-binding protein that has been implicated in multiple stages of cancer development. In this study, we investigated the role of transgelin in VM and assessed its effect on the expression of endothelial and angiogenesis-related genes during VM in MDA-MB-231 breast cancer cells. We confirmed the ability of MDA-MB-231 cells to undergo VM through a tube formation assay. Flow cytometry analysis revealed an increase in

APA, Harvard, Vancouver, ISO, and other styles

15

Galbraith, Susan M., Ross J. Maxwell, Martin A. Lodge, et al. "Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging." Journal of Clinical Oncology 21, no. 15 (2003): 2831–42. http://dx.doi.org/10.1200/jco.2003.05.187.

Full text

Abstract:

Purpose: Combretastatin A4 phosphate (CA4P) is a novel vascular targeting agent. Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) studies were performed to examine changes in parameters related to blood flow and vascular permeability in tumor and normal tissue after CA4P treatment. Materials and Methods: Changes in kinetic DCE-MRI parameters (transfer constant [Ktrans] and area under contrast medium-time curve [AUC]) over 24 hours after treatment with CA4P were measured in 18 patients in a phase I trial and compared with those obtained in the rat P22 carcinosarcoma model, using t

APA, Harvard, Vancouver, ISO, and other styles

16

Tuncel, Sinem, Aurélien Trivella, Devrim Atilla, et al. "Correction to “Assessing the Dual Activity of a Chalcone–Phthalocyanine Conjugate: Design, Synthesis, and Antivascular and Photodynamic Properties”." Molecular Pharmaceutics 12, no. 2 (2015): 663. http://dx.doi.org/10.1021/mp5008426.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Siim, Bronwyn, Alan Lee, Sahar Shalal-Zwain, Frederik Pruijn, Mark McKeage, and William Wilson. "Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)." Cancer Chemotherapy and Pharmacology 51, no. 1 (2003): 43–52. http://dx.doi.org/10.1007/s00280-002-0529-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Cecic, Ivana, Denise A. Chan, Patrick D. Sutphin, et al. "Oxygen Sensitivity of Reporter Genes: Implications for Preclinical Imaging of Tumor Hypoxia." Molecular Imaging 6, no. 4 (2007): 7290.2007.00017. http://dx.doi.org/10.2310/7290.2007.00017.

Full text

Abstract:

Reporter gene techniques have been applied toward studying the physiologic phenomena associated with tumor hypoxia, a negative prognostic indicator. The purpose of this study was to assess the potential adverse effects of hypoxic conditions on the effectiveness of four commonly used reporter genes: Renilla luciferase, monomeric red fluorescent protein, thymidine kinase, and lacZ. Tumor-forming A375 cells expressing a trifusion reporter consisting of Renilla luciferase, monomeric red fluorescent protein, and thymidine kinase were subjected to decreasing oxygen tensions and assayed for reporter

APA, Harvard, Vancouver, ISO, and other styles

19

Xia, Lin-Ying, Ya-Liang Zhang, Rong Yang, et al. "Tubulin Inhibitors Binding to Colchicine-Site: A Review from 2015 to 2019." Current Medicinal Chemistry 27, no. 40 (2020): 6787–814. http://dx.doi.org/10.2174/0929867326666191003154051.

Full text

Abstract:

Due to the three domains of the colchicine-site which is conducive to the combination with small molecule compounds, colchicine-site on the tubulin has become a common target for antitumor drug development, and accordingly, a large number of tubulin inhibitors binding to the colchicine-site have been reported and evaluated over the past years. In this study, tubulin inhibitors targeting the colchicine-site and their application as antitumor agents were reviewed based on the literature from 2015 to 2019. Tubulin inhibitors were classified into ten categories according to the structural features

APA, Harvard, Vancouver, ISO, and other styles

20

Chan, C. K., and S. G. Lin. "Retinal Pigment Epithelial Tear after Ranibizumab Therapy for Subfoveal Fibrovascular Pigment Epithelial Detachment." European Journal of Ophthalmology 17, no. 4 (2007): 674–76. http://dx.doi.org/10.1177/112067210701700432.

Full text

Abstract:

Purpose To describe the unusual complication of retinal pigment epithelial (RPE) tear after intravitreal ranibizumab (Lucentis®) for subfoveal fibrovascular pigment epithelial detachment (PED) and its effective management. Methods Chart review for case report of RPE tear after ranibizumab. Results An inferior RPE tear was documented by fluorescein angiography, fundus photography, and optical coherence tomography (OCT) 1 month after receiving repeat ranibizumab injection in the right eye of a patient with bilateral subfoveal fibrovascular PED. He had undergone multiple bevacizumab followed by r

APA, Harvard, Vancouver, ISO, and other styles

21

Lavazza, Cristiana, Carmelo Carlo-Stella, Arianna Giacomini, et al. "Human CD34+ cells engineered to express membrane-bound tumor necrosis factor–related apoptosis-inducing ligand target both tumor cells and tumor vasculature." Blood 115, no. 11 (2010): 2231–40. http://dx.doi.org/10.1182/blood-2009-08-239632.

Full text

Abstract:

Abstract Adenovirus-transduced CD34+ cells expressing membrane-bound tumor necrosis factor–related apoptosis-inducing ligand (CD34-TRAIL+ cells) exert potent antitumor activity. To further investigate the mechanism(s) of action of CD34-TRAIL+ cells, we analyzed their homing properties as well as antitumor and antivascular effects using a subcutaneous myeloma model in immunodeficient mice. After intravenous injection, transduced cells homed in the tumor peaking at 48 hours when 188 plus or minus 25 CD45+ cells per 105 tumor cells were detected. Inhibition experiments showed that tumor homing of

APA, Harvard, Vancouver, ISO, and other styles

22

Pohlmann, Dominika, Uwe Pleyer, Antonia M. Joussen, and Sibylle Winterhalter. "Immunosuppressants and/or antivascular endothelial growth factor inhibitors in punctate inner choroidopathy? Follow-up results with optical coherence tomography angiography." British Journal of Ophthalmology 103, no. 8 (2018): 1152–57. http://dx.doi.org/10.1136/bjophthalmol-2018-312455.

Full text

Abstract:

PurposeTo report the effectiveness of treatment with antivascular endothelial growth factor (VEGF)-inhibitor and/or immunosuppressants in punctate inner choroidopathy (PIC) using standard imaging modalities and optical coherence tomography angiography (OCTA) over a time period of 16 months.MethodsIn this prospective, unmasked, single-centre study, 23 individuals with PIC underwent imaging with spectral domain OCT, fluorescein angiography, indocyanine green angiography and OCTA. Two groups were formed based on systemic treatment. In case of choroidal neovascularisation (CNV) activity, intravitr

APA, Harvard, Vancouver, ISO, and other styles

23

Fanale, Daniele, Giuseppe Bronte, Francesco Passiglia, et al. "Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?" Analytical Cellular Pathology 2015 (2015): 1–19. http://dx.doi.org/10.1155/2015/690916.

Full text

Abstract:

Microtubules are dynamic and structural cellular components involved in several cell functions, including cell shape, motility, and intracellular trafficking. In proliferating cells, they are essential components in the division process through the formation of the mitotic spindle. As a result of these functions, tubulin and microtubules are targets for anticancer agents. Microtubule-targeting agents can be divided into two groups: microtubule-stabilizing, and microtubule-destabilizing agents. The former bind to the tubulin polymer and stabilize microtubules, while the latter bind to the tubul

APA, Harvard, Vancouver, ISO, and other styles

24

Shaib, Walid, Scott Kono, and Nabil Saba. "Antiepidermal Growth Factor Receptor Therapy in Squamous Cell Carcinoma of the Head and Neck." Journal of Oncology 2012 (2012): 1–11. http://dx.doi.org/10.1155/2012/521215.

Full text

Abstract:

Squamous cell carcinoma of head and neck (SCCHN) is the most common neoplasm of the upper aerodigestive tract. In this paper, we attempt to summarize the role and applications of the epidermal growth factor receptor (EGFR) inhibitors monoclonal antibodies (moAbs) and tyrosine kinase inhibitors (TKIs) locally advanced as well as metastatic SCCHN. Targeted therapy in SCCHN is now incorporated in the first-line regimes for advanced disease. Novel targeted agents, including the EGFR antibody, cetuximab, have been approved for use as single agents or in combination with radiation therapy or chemoth

APA, Harvard, Vancouver, ISO, and other styles

25

Corti, Angelo, Monica Giovannini, Carmen Belli, and Eugenio Villa. "Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF." Journal of Oncology 2010 (2010): 1–8. http://dx.doi.org/10.1155/2010/732680.

Full text

Abstract:

Standard treatments for nonsmall cell lung cancer (NSCLC), such as surgery, chemotherapy, and radiotherapy, often lead to disappointing results. Unfortunately, also the various immunotherapeutic approaches so far tested have not produced satisfactory results to be widely applied in the clinical practice. However, the recent development of new immunomodulatory agents may open promising therapeutic options. This paper focuses on PF3512676, lenalidomide, and NGR-TNF, that is, drugs belonging to three different classes of immunomodulatory agents, that are also capable to affect tumor blood vessels

APA, Harvard, Vancouver, ISO, and other styles

26

Patel, Vijay K., and Harish Rajak. "Development of Structure Activity Correlation Model on Aroylindole Derivatives as Anticancer Agents." Letters in Drug Design & Discovery 15, no. 2 (2018): 143–53. http://dx.doi.org/10.2174/1570180814666170823161751.

Full text

Abstract:

Background: Aroylindole derivatives, the structural analogs of Combretastatin A-4 has been found to possess potent growth inhibitory activity on several cancer cell lines due to its excellent antitumor and antivascular activities. The aim of present research work is to identify lead and establish structure activity correlation of trimethoxyaroylindole derivatives, using integrated ligand and structure based computational approaches. Materials and Methods: A correlation between structure and biological activity was established using computational approaches i.e., structure activity correlation

APA, Harvard, Vancouver, ISO, and other styles

27

Yan, Wei, Tao Yang, Jianhong Yang, et al. "SKLB060 Reversibly Binds to Colchicine Site of Tubulin and Possesses Efficacy in Multidrug-Resistant Cell Lines." Cellular Physiology and Biochemistry 47, no. 2 (2018): 489–504. http://dx.doi.org/10.1159/000489983.

Full text

Abstract:

Background/Aims: Many tubulin inhibitors are in clinical use as anti-cancer drugs. In our previous study, a novel series of 4-substituted coumarins derivatives were identified as novel tubulin inhibitors. Here, we report the anti-cancer activity and underlying mechanism of one of the 4-substituted coumarins derivatives (SKLB060). Methods: The anti-cancer activity of SKLB060 was tested on 13 different cancer cell lines and four xenograft cancer models. Immunofluorescence staining, cell cycle analysis, and tubulin polymerization assay were employed to study the inhibition of tubulin. N, N ′-Ethy

APA, Harvard, Vancouver, ISO, and other styles

28

Zhang, Xinyuan, and Timothy Y. Y. Lai. "Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration." BioMed Research International 2018 (2018): 1–10. http://dx.doi.org/10.1155/2018/9640131.

Full text

Abstract:

Age-related macular degeneration (AMD) is one of the leading causes of severe vision loss in people over 60 years. Wet AMD (wAMD) causes more severe visual acuity (VA) loss compared with the dry form due to formation of choroidal neovascularization (CNV). Antivascular endothelial growth factor (anti-VEGF) agents such as ranibizumab and aflibercept are now the standard of care treatment for wAMD. Unfortunately, up to a quarter of anti-VEGF-treated wAMD patients might not fully benefit from intravitreal injections and CNV activity may not respond to the treatment and these patients are called an

APA, Harvard, Vancouver, ISO, and other styles

29

Parasramka, Mansi, David A. Proia, and Richard Wayne Joseph. "Preclinical activity of the heat shock protein 90 inhibitor ganetespib in clear cell renal cell carcinoma." Journal of Clinical Oncology 32, no. 4_suppl (2014): 478. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.478.

Full text

Abstract:

478 Background: Resistance invariably develops in all patients with metastatic ccRCC treated with mTOR inhibitors. Previously we demonstrated that dual inhibition of Hsp90 and the mTOR pathway in lung cancer models leads to synergistic reductions in tumor growth. Herein, we tested the efficacy of ganetespib as a single agent and in combination with mTOR inhibition using in vitro and in vivoccRCC models. Methods: For the in vitro work we utilized the following seven ccRCC cell lines: Caki-1, Caki-2, A-498, A-704, 769-P, 786-O, ACHN. For the in vivo work we used A498 xenografts. In vitro, we det

APA, Harvard, Vancouver, ISO, and other styles

30

Heo, J., D. H. Kirn, C. Breitbach, et al. "Evaluating antivascular effects and antitumoral activity in patients with hepatocellular carcinoma treated with JX-594, a targeted multimechanistic oncolytic poxvirus, prior to sorafenib therapy." Journal of Clinical Oncology 28, no. 15_suppl (2010): e14564-e14564. http://dx.doi.org/10.1200/jco.2010.28.15_suppl.e14564.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Schmitt, Florian, Kate Donnelly, Julienne K. Muenzner, et al. "Effects of histidin-2-ylidene vs. imidazol-2-ylidene ligands on the anticancer and antivascular activity of complexes of ruthenium, iridium, platinum, and gold." Journal of Inorganic Biochemistry 163 (October 2016): 221–28. http://dx.doi.org/10.1016/j.jinorgbio.2016.07.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Faatz, Henrik, Marie-Louise Farecki, Kai Rothaus, Matthias Gutfleisch, Daniel Pauleikhoff, and Albrecht Lommatzsch. "Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment." BMJ Open Ophthalmology 4, no. 1 (2019): e000369. http://dx.doi.org/10.1136/bmjophth-2019-000369.

Full text

Abstract:

ObjectiveOptical coherence tomography angiography (OCT-A) enables detailed visualisation of the vascular structure of choroidal neovascularisation (CNV). The aim of this study was to determine whether mathematically ascertained OCT-A vascular parameters of type 1 and type 2 CNV in exudative age-related macular degeneration (AMD) change during antivascular endothelial growth factor (anti-VEGF) treatment. The OCT-A vascular parameters were also compared with previously obtained activity parameters (fluid distribution on spectral domain OCT (SD-OCT)) to establish whether they could potentially be

APA, Harvard, Vancouver, ISO, and other styles

33

Antonelli, Alessandro, Guido Bocci, Concettina La Motta, et al. "Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer." Endocrinology 152, no. 1 (2011): 334. http://dx.doi.org/10.1210/endo.152.1.9995.

Full text

Abstract:

Aim: We have studied the antitumoral activity of two new pyrazolo[3,4-d]pyrimidine compounds (CLM3 and CLM29) in primary papillary dedifferentiated thyroid cancer cells (DePTC cells). Methods: The antiproliferative effect was tested in DePTC cells obtained at reoperation from patients with recurrence of the tumor. The concentrations of CLM3 and CLM29 used in the in vitro experiments were 1, 10, 30, and 50 μm. Results: Proliferation assays in DePTC cells showed a significant reduction of proliferation by CLM3 and CLM29, which was by 12% with CLM3 (the most potent compound) 10 μm, 43% with CLM3

APA, Harvard, Vancouver, ISO, and other styles

34

Robbins, Cason B., Henry L. Feng, and Sharon Fekrat. "Quiescent Neovascular Age-Related Macular Degeneration After Endophthalmitis." Journal of VitreoRetinal Diseases 4, no. 4 (2020): 300–305. http://dx.doi.org/10.1177/2474126420914282.

Full text

Abstract:

Purpose: This article describes eyes that achieved extended remission of neovascular age-related macular degeneration (NVAMD) following acute endophthalmitis. Methods: Adults who presented to the Duke Eye Center with acute endophthalmitis over a 9-year period and had at least 3 months of follow-up were identified. A retrospective review of medical records was performed to collect clinical data including demographic information, examination findings, etiology, treatment, and outcomes. Results: A total of 133 eyes of 130 patients with endophthalmitis were identified. Of these, 15 eyes of 14 pati

APA, Harvard, Vancouver, ISO, and other styles

35

Gasparini, Giampietro, Raffaele Longo, Massimo Fanelli, and Beverly A. Teicher. "Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions." Journal of Clinical Oncology 23, no. 6 (2005): 1295–311. http://dx.doi.org/10.1200/jco.2005.10.022.

Full text

Abstract:

Angiogenesis is necessary for tumor growth. Drug discovery efforts have identified several potential therapeutic targets on endothelial cells and selective inhibitors capable of slowing tumor growth or producing tumor regression by blocking angiogenesis in in vivo tumor models. Certain antiangiogenic therapeutics increase the activity of cytotoxic anticancer treatments in preclinical models. More than 75 antiangiogenic compounds have entered clinical trials. Most of the early clinical testing was conducted in patients with advanced disease resistant to standard therapies. Several phase III tri

APA, Harvard, Vancouver, ISO, and other styles

36

Ghinea, Nicolae. "Anti-Angiogenic Therapy: Albumin-Binding Proteins Could Mediate Mechanisms Underlying the Accumulation of Small Molecule Receptor Tyrosine Kinase Inhibitors in Normal Tissues with Potential Harmful Effects on Health." Diseases 9, no. 2 (2021): 28. http://dx.doi.org/10.3390/diseases9020028.

Full text

Abstract:

Anti-angiogenics currently used in cancer therapy target angiogenesis by two major mechanisms: (i) neutralizing angiogenic factors or their receptors by using macromolecule anti-angiogenic drugs (e.g., therapeutic antibodies), and (ii) blocking intracellularly the activity of receptor tyrosine kinases with small molecule (Mr < 1 kDa) inhibitors. Anti-angiogenics halt the growth and spread of cancer, and significantly prolong the disease-free survival of the patients. However, resistance to treatment, insufficient efficacy, and toxicity limit the success of this antivascular therapy. Publish

APA, Harvard, Vancouver, ISO, and other styles

37

Baselga, José, and Carlos L. Arteaga. "Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer." Journal of Clinical Oncology 23, no. 11 (2005): 2445–59. http://dx.doi.org/10.1200/jco.2005.11.890.

Full text

Abstract:

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB receptor family that is abnormally activated in many epithelial tumors. The aberrant activation of the EGFR leads to enhanced proliferation and other tumor-promoting activities, which provide a strong rationale to target this receptor family. There are two classes of anti-EGFR agents: monoclonal antibodies (MAbs) directed at the extracellular domain of the receptor and small molecule, adenosine triphosphate–competitive inhibitors of the receptor's tyrosine kinase. Anti-EGFR MAbs have shown antitumor activity

APA, Harvard, Vancouver, ISO, and other styles

38

Ty, Nancy, Grégory Dupeyre, Guy G. Chabot, et al. "Structure–activity relationships of indole compounds derived from combretastatin A4: Synthesis and biological screening of 5-phenylpyrrolo[3,4-a]carbazole-1,3-diones as potential antivascular agents." European Journal of Medicinal Chemistry 45, no. 9 (2010): 3726–39. http://dx.doi.org/10.1016/j.ejmech.2010.05.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Gallo-Stampino, C., G. Rizzardi, S. Toma, et al. "Safety and anticancer activity of low dose regimen of NGRhTNF, a new vascular targeting agent, in solid advanced malignancies (NGR002 phase I trial)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 3540. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.3540.

Full text

Abstract:

3540 Background: NGRhTNF is a vascular targeting agent (VTA) exploiting a tumour homing peptide (CNGRCG) selectively binding angiogenic vessels in solid tumours where NGRhTNF specific binding relies on dynamic interactions with TNF-receptors and aminopeptidase N (CD13). NGRhTNF combines activity on tumour vascular permeability and direct anticancer activity. Consistently, mouse preclinical data indicate significant synergy between low dose NGRhTNF and cytotoxic agents. Methods: 4 dose levels of NGRhTNF (0.2 up to 1.6 mcg/sqm) have been administered q 3 w in 16 patients. Main end-points include

APA, Harvard, Vancouver, ISO, and other styles

40

Moiseeva, E. V., N. R. Kuznetsova, E. V. Svirshchevskaya, et al. "Liposome formulations of combretastatin a4 and 4-arylcoumarin analog prodrugs: antitumor effect in the mouse model of breast cancer." Biomeditsinskaya Khimiya 58, no. 3 (2012): 326–38. http://dx.doi.org/10.18097/pbmc20125803326.

Full text

Abstract:

The antimitotic agent combretastatin A4 (СА-4) has been suggested as an antivascular agent for anticancer therapy relatively recently. To reduce systemic toxicity by means of administration in liposome formulations, in this study new lipophilic prodrugs, oleic derivatives of СА-4 and its 4-arylcoumarin analog (СА4-Ole and ArC-Ole, respectively), have been synthesized: Liposomes of 100 nm mean diameter prepared on the basis of egg phosphatidylcholine and phosphatidylinositol from bakers yeast have been shown to include completely up to 10 mol. % of СА4-Ole, or 7 mol. % of ArC-Ole. Also, prodrug

APA, Harvard, Vancouver, ISO, and other styles

41

Abdelmotaal, Hazem, Walid Ibrahim, Mohamed Sharaf, and Khaled Abdelazeem. "Causes and Clinical Impact of Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy." Journal of Ophthalmology 2020 (February 8, 2020): 1–8. http://dx.doi.org/10.1155/2020/7691724.

Full text

Abstract:

Purpose. This study determined the clinical impact and causes of loss to follow-up (LTFU) from the patients’ perspective in individuals with proliferative diabetic retinopathy (PDR) who received panretinal photocoagulation (PRP) and/or intravitreal injections (IVIs) of antivascular endothelial growth factor (VEGF). Methods. This prospective cohort study included 467 patients with PDR who received PRP and/or IVIs of anti-VEGF between May 2013 and June 2018. LTFU was defined as missing any follow-up visit for any interval exceeding 6 months, provided that patients eventually resumed care. Main o

APA, Harvard, Vancouver, ISO, and other styles

42

Chhablani, Jay, Remya Mareen Paulose, Andres F. Lasave, et al. "Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group." British Journal of Ophthalmology 102, no. 4 (2017): 455–59. http://dx.doi.org/10.1136/bjophthalmol-2017-310411.

Full text

Abstract:

PurposeTo report the long-term anatomical and visual outcomes of intravitreal bevacizumab (IVB) monotherapy in naive choroidal neovascularisation (CNV) caused by myopia.MethodsRetrospective analysis of naive CNV secondary to myopia that underwent antivascular endothelial growth factor monotherapy was performed. Collected data included demographic details, clinical examination details including visual acuity at presentation and follow-up with imaging and treatment details. Main outcome measures were resolution of CNV activity at the last visit. Secondary outcomes included change in visual acuit

APA, Harvard, Vancouver, ISO, and other styles

43

Zhu, Andrew X., Dushyant V. Sahani, Dan G. Duda, et al. "Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study." Journal of Clinical Oncology 27, no. 18 (2009): 3027–35. http://dx.doi.org/10.1200/jco.2008.20.9908.

Full text

Abstract:

PurposeTo assess the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) and explore biomarkers for sunitinib response.Patients and MethodsWe conducted a multidisciplinary phase II study of sunitinib, an antivascular endothelial growth factor receptor tyrosine kinase inhibitor, in advanced HCC. Patients received sunitinib 37.5 mg/d for 4 weeks followed by 2 weeks of rest per cycle. The primary end point was progression-free survival (PFS). We used functional magnetic resonance imaging to evaluate vascular changes in HCC after sunitinib treatment. Circulati

APA, Harvard, Vancouver, ISO, and other styles

44

Bulotta, Alessandra, Vanesa Gregorc, Gilda Rossoni, et al. "Relationships of peripheral blood lymphocyte counts (PBLC) with antitumor activity of NGR-hTNF given in combination with chemotherapy (CT)." Journal of Clinical Oncology 31, no. 15_suppl (2013): 3038. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3038.

Full text

Abstract:

3038 Background: Antitumor effects of NGR-hTNF (N), a tumor-targeted antivascular agent, are driven at low dose by an early vessel stabilization that greatly enhances both intratumoral CT uptake and T-cell infiltration. Synergism with CT was shown in immunocompetent mice, but not in nude mice lacking functional T cells. Methods: By an individual patient pooled analysis of 396 patients (pts) from 7 ph II trials in 6 tumor types, we estimated the effects of baseline PBLC on the antitumor activity of N (with or without CT) and CT alone. Low dose N (0.8 μg/m2) was given in combination with CT in 1

APA, Harvard, Vancouver, ISO, and other styles

45

Segaoula, Zacharie, Julien Leclercq, Valérie Verones, et al. "Synthesis and Biological Evaluation of N-[2-(4-Hydroxyphenylamino)-pyridin-3-yl]-4-methoxy-benzenesulfonamide (ABT-751) Tricyclic Analogues as Antimitotic and Antivascular Agents with Potent in Vivo Antitumor Activity." Journal of Medicinal Chemistry 59, no. 18 (2016): 8422–40. http://dx.doi.org/10.1021/acs.jmedchem.6b00847.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Anderson, Pete M., Jacob Scott, Shireen Parsai, et al. "223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy." ESMO Open 5, no. 2 (2020): e000635. http://dx.doi.org/10.1136/esmoopen-2019-000635.

Full text

Abstract:

BackgroundBone-seeking radiopharmaceuticals can deposit radiation selectively to some osteosarcoma tumours because of the bone-forming nature of this cancer.ObjectivesThis is the first report of using 223-radium, an alpha-emitting calcium analogue with a high therapeutic index, in combination therapy with other agents in 15 patients with metastatic osteoblastic osteosarcoma.MethodsCandidates for alpha-radiotherapy if 99mTc-MDP bone scan had avid bone-forming lesions and no therapy of higher priority (eg, definitive surgery). Monthly 223-radium infusions (1.49 μCi/kg or 55.13 kBq/kg) were given

APA, Harvard, Vancouver, ISO, and other styles

47

de Groot, John F., Kathleen R. Lamborn, Susan M. Chang, et al. "Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study." Journal of Clinical Oncology 29, no. 19 (2011): 2689–95. http://dx.doi.org/10.1200/jco.2010.34.1636.

Full text

Abstract:

Purpose Antivascular endothelial growth factor (anti-VEGF) therapy is a promising treatment approach for patients with recurrent glioblastoma. This single-arm phase II study evaluated the efficacy of aflibercept (VEGF Trap), a recombinantly produced fusion protein that scavenges both VEGF and placental growth factor in patients with recurrent malignant glioma. Patients and Methods Forty-two patients with glioblastoma and 16 patients with anaplastic glioma who had received concurrent radiation and temozolomide and adjuvant temozolomide were enrolled at first relapse. Aflibercept 4 mg/kg was adm

APA, Harvard, Vancouver, ISO, and other styles

48

Choo, Su Pin, Quan Sing Ng, Wallace Jian Jun Chen, et al. "A phase I/II study of AZD6244 in combination with sorafenib in advanced hepatocellular carcinoma." Journal of Clinical Oncology 30, no. 15_suppl (2012): 4100. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4100.

Full text

Abstract:

4100^ Background: Preclinical studies have shown that pharmacological inhibition of the MEK/ERK pathway by AZD6244 enhanced the anti-tumor effect of sorafenib in both orthotopic and ectopic models of HCC. We conducted this study to determine tolerability, pharmacokinetics, and pharmacodynamics of AZD6244 when combined with sorafenib in advanced HCC. Methods: Patients with biopsy-proven unresectable BCLC B/C hepatocellular carcinoma were recruited. Only those with Childs-Pugh A or B (7) liver cirrhosis and without prior systemic therapy were included. Sorafenib at 400mg bd was given 1 week befo

APA, Harvard, Vancouver, ISO, and other styles

49

Cetnar, J. P., M. A. Rosen, D. J. Vaughn, et al. "Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC)." Journal of Clinical Oncology 27, no. 15_suppl (2009): e16055-e16055. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e16055.

Full text

Abstract:

e16055 Background: Previous trials of the antiangiogenic kinase inhibitor sorafenib in mCRPC have reported PSA elevation accompanying radiographic response, and evidence that sorafenib may potentiate docetaxel (dxl) myelosuppression. To assess the safety, antivascular effects, and activity of sorafenib and dxl in mCRPC, a phase II trial with dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) was conducted. Methods: Eligible men had mCRPC and no prior chemotherapy. Treatment consisted of dxl 75 mg/m2(day 1) and sorafenib (days 2–19) of a 21 day cycle. Patients received 7 days of sor

APA, Harvard, Vancouver, ISO, and other styles

50

Zucali, Paolo A., Matteo Simonelli, Fabio De Vincenzo, Armando Santoro, Antonio Lambiase, and Claudio Bordignon. "Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF." Journal of Clinical Oncology 31, no. 15_suppl (2013): e22145-e22145. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e22145.

Full text

Abstract:

e22145 Background: Dose-response curve of NGR-hTNF, a selective antivascular agent, is typically biphasic with activity shown either at low dose (LD) or high dose (HD). Receptor shedding may block drug activity. Vascular effects at LD are characterized by early vessel stabilization and late vessel damage, while at HD by rapid vessel disruption. Methods: 60 pts (median age: 61; M/F: 44/16; PS 0/≥1: 25/35; median prior lines: 3) received in 2 ph I trials NGR-hTNF at LD (0.2-1.6 µg/m2; n=14) or HD (60-325 µg/m2; n=46) every 3 weeks. We tested the impact of early changes (post 1st dose) in baselin

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!